Atai Life Sciences N.V. (ATAI)
After hours:
| Previous Close | 1.8200 |
| Open | 1.8100 |
| Bid | 1.7800 x 2200 |
| Ask | 1.7900 x 1400 |
| Day's Range | 1.7700 - 1.8400 |
| 52 Week Range | 1.4500 - 6.3200 |
| Volume | |
| Avg. Volume | 1,479,988 |
| Market Cap | 296.916M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3990 |
| Earnings Date | Nov 10, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.58 |
- News Direct
Trippy Trading: Top Psychedelic Stocks For 2023
When psychedelics were first studied more than 50 years ago, researchers discovered that they were useful in assisting people in exploring a greater sense of self. After a half-century hiatus, scie...
- Market Exclusive
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
Key Takeaways; Cannabis Sector Leafly Holdings started the year with strong market performance. Innovative Industrial Properties’ market performance remained robust, following the announcement of significant dividends for 2022. Columbia Care subsidiary is carrying out large-scale cannabis industry layoffs. Key Takeaways; Psychedelic Sector Awakn’s ketamine-assisted psychotherapy for the treatment of AUD was ranked as the 5th […] The post Weekly Roundup on the Cannabis Sector & Psychedelic Sector
- GlobeNewswire
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
GRX-917 (deuterated etifoxine) was well-tolerated with no dose-limiting toxicities and only mild adverse effects comparable to that of placebo in both single and multiple ascending doses, as previously announced as preliminary results during atai’s R&D day.Final results demonstrate target engagement of GRX-917 via dose-related activation of quantitative electroencephalography (qEEG) frontal beta power, a biomarker for GABA-A receptor-associated anxiolytic activity, consistent with GRX-917’s puta
